VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PYXS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PYXSPyxis Oncology, Inc.
$1.44$91M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PYXS logo

Pyxis Oncology, Inc.

PYXS
NASDAQ · Oncology Biotech
$1.44
At close - Nov 17, 4:00 PM EST - USD
Market Cap$91M
P/E-1.4x
52W High$5.55
Volume1.43M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Clinical Capital Exhaustion Threatens Pyxis Oncology Viability

Pyxis Oncology faces a precarious financial outlook as its reliance on non-recurring milestone payments fails to offset consistent, high-intensity R&D expenditures.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

PYXS price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-105% Peers

P/E is 105% below peer median

03

Market leadership

RS 21 · Lag

Laggard (Underperforming 79% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PYXS+25.22%
S&P 500 (^GSPC)+7.21%
1-Year Return
PYXS-69.03%
S&P 500 (^GSPC)+10.03%
3-Year Return
PYXS+0.70%
S&P 500 (^GSPC)+69.26%
5-Year Return
PYXS-88.54%
S&P 500 (^GSPC)+54.65%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$14M-14.2% YoY
Net income FY25
-$80M-3.0% YoY
Free cash flow FY25
-$64M-9.7% YoY
Operating margin FY25
-609.2%-55.1 pts YoY
ROIC (FY25)-71.1%
Avg ROIC 5Y-70.8%
ROE (TTM)-252.4%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate3/12 (100%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$0.24+11.1%
vs -$0.27
—
vs $19,440
Q3 2026
Aug 13, 2026
-$0.40-14.3%
vs -$0.35
—
vs $33,333
Q2 2026
May 14, 2026
-$0.37-5.7%
vs -$0.35
—
vs $19,440
Q2 2026
Mar 23, 2026
-$0.29+17.1%
vs -$0.35
$11M+8730.4%
vs $125,000
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Oct 28, 2026
Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, will participate in fireside chats at two upcoming conferences.

GlobeNewsWire·Oct 27, 2026
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 - November 20, 2026.

Defense World·Oct 10, 2026
Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis

Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Institutional and Insider Ownership 33.5% of Precigen shares are

Seeking Alpha·Oct 4, 2026
Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D

PYXS's main value driver is MICVO. This is an oncology drug candidate that could be useful for killing cancerous cells. MICVO's early data has been promising, but PYXS still has to find an adequate dose that's safe and effective. Fortunately, PYXS's recent raise helps their financing in the near term and should be enough for them to reach important clinical milestones with MICVO.

Filtered for Pyxis Oncology, Inc.More Headlines
04

Compare before deciding

Benchmark PYXS against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Pyxis Oncology, Inc. (PYXS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PYXS logoPYXSPyxis Oncology, Inc.Current
$1.44$91.23M-1.39-14.17%-785.54%-252.36%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
RCUS logoRCUSArcus Biosciences, Inc.
$16.39$2.06B-4.69-4.26%-445%-90.04%—
TPST logoTPSTTempest Therapeutics, Inc.
$0.33$4.98M-0.12——-1270.11%—
AGIO logoAGIOAgios Pharmaceuticals, Inc.
$29.89$1.78B-4.7948.03%-264.76%-34.63%—
MGNX logoMGNXMacroGenics, Inc.
$2.05$130.3M-2.540.78%-45.37%-142.22%—

Compare PYXS vs Peers

Pyxis Oncology, Inc. (PYXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for PYXS.

Scale Benchmark

vs MRK

Larger-name benchmark to compare PYXS against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, RCUS, TPST, AGIO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PYXS SEC Filings & Documents

Pyxis Oncology, Inc. (PYXS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 13, 2026·SEC

Material company update

Jul 2, 2026·SEC

Material company update

Jun 15, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 18, 2025·SEC

FY 2024

Mar 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 13, 2026·SEC

FY 2026

May 14, 2026·SEC

FY 2025

Nov 3, 2025·SEC

Get notified when PYXS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PYXS Frequently Asked Questions

Pyxis Oncology, Inc. (PYXS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Pyxis Oncology, Inc.'s revenue?

Pyxis Oncology, Inc. (PYXS) reported $11.0M in revenue over the trailing twelve months. Revenue was $13.9M in fiscal year 2025.

How fast is Pyxis Oncology, Inc. growing?

Pyxis Oncology, Inc. (PYXS) grew revenue by 291.4% over the trailing twelve months, compared with the twelve months before.

Is PYXS profitable?

No. Pyxis Oncology, Inc. (PYXS) reported a net loss of $86.7M over the trailing twelve months.

Dividend & Returns
What is PYXS's return on equity?

Pyxis Oncology, Inc. (PYXS) had a return on equity (ROE) of -252.4% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Pyxis Oncology, Inc.'s free cash flow?

Pyxis Oncology, Inc. (PYXS) had negative free cash flow of $70.9M over the trailing twelve months.

What if you invested $1,000 in PYXS back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →